Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study / Brandes, ; A., A.; Finocchiaro, ; Zagonel, ; Reni, M; Fabi, ; Caserta, ; Tosoni, ; Eoli, ; Lombardi, ; Clavarezza, ; Paccapelo, ; Bartolini, ; Cirillo, ; Agati, ; Franceschi,. - In: ONCOTARGET. - ISSN 1949-2553. - (2017).
Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study
Reni M;
2017-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
